Rheumatoid Factor vs Anti-CCP: What Each Rheumatoid Arthritis Blood Test Measures, Which Is More Accurate, and Why You Usually Want Both

Rheumatoid arthritis is diagnosed from the joints — which ones, how many, for how long — with blood tests adding weight, and two antibodies carry that weight. Rheumatoid factor is an autoantibody (usually IgM) directed at the tail of your own IgG antibodies. It was the first marker found, it gave the disease its name, and it is sensitive but not specific: present in about two-thirds of people with RA, but also in Sjögren's syndrome, chronic hepatitis C, bacterial endocarditis and other long infections, lupus, sarcoidosis, interstitial lung disease and some cancers, and in a growing share of healthy people as they age. Anti-CCP is an antibody to citrullinated proteins — proteins altered by an enzyme that is active in inflamed rheumatoid joints — and the immune response to them is nearly unique to RA. It finds about the same two-thirds of patients, but a positive result means RA with roughly 95% specificity, it can be detected years before symptoms, and it marks the patients most likely to develop joint erosions. The two tests overlap but do not duplicate: some patients are positive for only one, and the 2010 ACR/EULAR criteria give points for whichever is positive and more points for a high level. Order both when joint pain, swelling or morning stiffness has lasted more than a few weeks — and remember that a quarter of true RA is negative on both.

RF is reported in IU/mL; at Quest and Labcorp a value under 14 IU/mL is negative. It measures IgM antibodies that bind the Fc portion of IgG — in effect, antibodies against antibodies. In RA those immune complexes deposit in the joint lining and drive inflammation, and higher titers go with more active, more erosive disease and with the extra-articular features (nodules, lung and eye involvement). Pooled across studies, RF is positive in about 69% of people with RA and negative in about 85% of people without it.

The 15% false-positive rate is the catch, and it is not random. RF is positive in roughly 75–95% of people with Sjögren's syndrome, in most people with hepatitis C–associated cryoglobulinemia, in 20–30% of people with lupus, in chronic infections (endocarditis, tuberculosis, syphilis, viral hepatitis), in sarcoidosis, interstitial lung disease and some lymphomas — and in 5–10% of healthy adults, rising to one in five or more past 70. A low-positive RF in an older adult with osteoarthritis pain is therefore a common and usually meaningless finding; a high-positive RF (more than three times the upper limit, so above about 42 IU/mL) in someone with swollen small joints is a different matter. The rheumatoid factor biomarker page walks through the ranges.

Anti-CCP detects antibodies to cyclic citrullinated peptides — synthetic versions of the citrullinated proteins (fibrinogen, vimentin, enolase and others) found in rheumatoid joints. Citrullination is a normal chemical modification; in people with the genetic background for RA (the HLA-DRB1 "shared epitope"), especially smokers, the immune system starts treating those modified proteins as foreign. The test is reported in units: at Quest and Labcorp, under 20 is negative, 20–39 weak positive, 40–59 moderate positive and 60 or above strong positive. Pooled sensitivity is about 67% — essentially the same as RF — but pooled specificity is about 95%, and in some series higher.

Three properties make it the more useful test. It is early: in stored blood-bank samples, anti-CCP was detectable a median of several years before patients developed RA, so a positive result in someone with new, undifferentiated joint pain strongly predicts progression. It is prognostic: anti-CCP–positive RA is more likely to erode bone and progress on x-ray, which pushes clinicians toward earlier, stronger disease-modifying treatment. And it is specific: unlike RF, it is rarely positive in Sjögren's, hepatitis C or healthy aging, so a positive anti-CCP in the right clinical setting is close to confirmatory. It is not perfect — low-positive results occur in psoriatic arthritis, tuberculosis and a few other conditions — which is why the criteria weight a strong positive more than a weak one.

Because the two tests find overlapping but different patients — some are RF-positive and anti-CCP–negative, some the reverse — and because the classification criteria score whichever is higher, the standard first-pass work-up for joint pain that has lasted more than six weeks is RF and anti-CCP together, with ESR and CRP (the criteria also award a point for an abnormal acute-phase reactant) and often an ANA, because lupus and other connective-tissue diseases present with the same joints. Through TestWell that is the Autoimmune Panel (RF, anti-CCP, ANA, hs-CRP, ESR) for $129.99, or the two antibodies alone for $19.99 + $32.99. The Autoimmune Screening Panel ($86.99) covers ANA, RF, hs-CRP and ESR without anti-CCP — the right choice when the question is "is this autoimmune at all" rather than "is this RA." Order anti-CCP alone when an RF has already come back positive and you need to know whether it means RA; order RF alone only when a clinician has asked for it specifically. The ESR vs CRP guide explains the two inflammation markers that travel with these.

• RF positive, anti-CCP positive. Rheumatoid arthritis is very likely, and double-positive disease tends to be more erosive — see a rheumatologist promptly; early disease-modifying treatment within the first months changes the long-term outcome.
• RF negative, anti-CCP positive. Still points firmly at RA (or at RA that has not fully declared itself) given the test's specificity. Low-positive values (20–39) are repeated and read with the joint exam; moderate or strong positives are a rheumatology referral.
• RF positive, anti-CCP negative. The combination that needs the most thought. A high-positive RF with symmetric small-joint swelling is RA until proven otherwise; a low-positive RF with dry eyes and mouth suggests Sjögren's, with risk factors suggests hepatitis C (a hepatitis C antibody test settles it), and in an older adult with osteoarthritis-pattern pain is usually a bystander.
• Both negative. Lowers the odds but does not exclude RA — roughly 20–30% of patients are seronegative, and antibodies can turn positive later. Six weeks or more of joint swelling with morning stiffness over 30 minutes still warrants a clinician's exam; the alternatives (psoriatic arthritis, viral arthritis, gout, osteoarthritis, reactive arthritis) have their own tests.

Either antibody, once positive, generally stays positive; levels fall somewhat with treatment but are not used to track disease activity day to day — that is what the joint count, ESR and CRP are for.

Through TestWell, drawn at Quest or Labcorp with one $6 lab fee per order: Rheumatoid Factor $19.99 (results in 2–4 business days); Anti-CCP $32.99 (3–5 business days); Autoimmune Panel $129.99; Autoimmune Screening Panel $86.99; ANA $32.99. No fasting, no doctor's visit; a licensed physician authorizes the order, the requisition is emailed, most locations take walk-ins, and results post to your account with the lab's reference bands and a plain-language summary you can bring to a rheumatologist — who will want exactly these values at the first visit.

Ordering RF and anti-CCP yourself makes sense when joint pain or stiffness has lasted a few weeks and you want to arrive at the appointment with the numbers. See a clinician first, and soon, for: a hot, red, exquisitely painful single joint (possible infection or gout — same-day); joint swelling with fever, rash, weight loss or shortness of breath; new joint symptoms with a known positive hepatitis C or HIV status; or symptoms in a child. And treat a positive anti-CCP, or a high-positive RF with swollen joints, as a reason to be seen within weeks rather than months — the "window of opportunity" for rheumatoid arthritis is real, and the drugs that prevent joint damage work best when started early.